medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2022, Number 09

<< Back Next >>

Ginecol Obstet Mex 2022; 90 (09)

Recommendations for continuous glucose monitoring in pregnant patients with type 1, 2 and gestational diabetes mellitus

Martínez-Portilla RJ, Medina-Jiménez V, Cruz-Rodríguez IV, Reyes-Muñoz E, Chinolla-Arellano Zl, Galeana-Corrales E

Language: Spanish
References: 23
Page: 756-768
PDF size: 248.69 Kb.


ABSTRACT

Objective: To issue recommendations for the surveillance and follow-up of pregnant patients with types 1, 2 and gestational diabetes mellitus based on the experience of a group of experts and on what is reported in the literature, from the perspective of the Mexican health system.
Materials and Methods: A modified Delphi Panel methodology was performed, through consensus among gynecology, reproductive biologist, and fetal-maternal specialists, and an 80% consensus of all participants.
Results: Based on the consensus exercise, we recommend continuous glucose monitoring in all pregnant patients with type I and II diabetes starting on the first trimester; meanwhile in patients with gestational diabetes, continuous monitoring should be considered in patients treated with insulin or uncontrolled glycemia, starting in the second or third trimester, depending on the moment of diagnosis, glycemic levels and insulin requirements, taking into account HbA1c levels and time in range as well as glycemic control metrics.
Conclusions: Continuous glucose monitoring has advantages including the reduction of perinatal complications, timely detection, reduction in the number of hyper/ hypoglycemia events, fewer uncontrolled patients, and the capacity for insulin dosage adjustments and improvement of habits for glucose control.


REFERENCES

  1. Instituto Mexicano del Seguro Social. Diagnóstico y TratamientoFarmacológico de la Diabetes mellitus tipo 2 enel Primer Nivel de Atención. Guia de Evidencias y Recomendaciones:Guía de Práctica Clínica. México: InstitutoMexicano del Seguro Social, 2018. http://www.imss.gob.mx/sites/all/statics/guiasclinicas/718GER.pdf

  2. redGDPS. Guía de diabetes tipo 2 para clínicos: Recomendacionesde la redGDPS. España: BelloyMartínez.com,2018. https://www.redgdps.org/guia-de-diabetes-tipo-2-para-clinicos.

  3. Instituto Mexicano del Seguro Social. Diagnóstico y tratamientode la diabetes en el embarazo. Ciudad de México:Instituto Mexicano del Seguro Social, 2016. http://www.imss.gob.mx/sites/all/statics/guiasclinicas/320GER.pdf

  4. Ministerio de Salud Pública de Ecuador. Diagnóstico ytratamiento de la diabetes en el embarazo (pregestacionaly gestacional). Guía de Práctica Clínica. Quito: DirecciónNacional de Normatización, 2014. https://www.salud.gob.ec/wp-content/uploads/2016/09/GPC-Diabetes-enel-embarazo.pdf

  5. American Diabetes Association; 14. Management of Diabetesin Pregnancy: Standards of Medical Care in Diabetes-2021. Diabetes Care 1 January 2021; 44 (Supplement_1):S200–S210. https://doi.org/10.2337/dc21-S014

  6. Litwak León E, Querzoli Ivanna, Musso Carla, Dain Alejandro,et al. Monitoreo continuo de glucosa: Utilidade indicaciones. Medicina (B. Aires) 2019 feb; 79 (1):44-52. http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802019000100007&lng=es.

  7. Aberer F, Hochfellner DA, Mader JK. Application of Telemedicinein Diabetes Care: The Time is Now. DiabetesTher 2021; 12 (3): 629-639. https://doi.org/10.6084/m9.figshare.13483197

  8. Martínez-Sahuquillo Amuedo MC, Echevarría Ruiz De Vargas.Métodos de consenso. Uso adecuado de la evidenciaen la toma de decisiones. “Método RAND/UCLA”. Rehabilitación 2001; 35 (6): 388-92. https://doi.org/10.1016/S0048-7120(01)73220-3

  9. Ávila CM. Metodología Delphi en salud. Hipertensióny riesgo vascular 2015; 32 (Supl. 1): 12-16. https://doi.org/10.1016/S1889-1837(15)30003-9

  10. National Institute for Health and Care Excellence (NICE) Diabetesin pregnancy: management from preconception tothe postnatal period. https://www.nice.org.uk/guidance/ng3/resources/diabetes-in-pregnancy-management-frompreconception-to-the-postnatal-period-51038446021

  11. Battelino T, Danne T, Bergenstal RM, Amiel AS, et al. Clinicaltargets for continuous glucose monitoring data interpretation:recommendations from the International Consensuson Time in Range. Diabetes Care 2019; 42 (8):1593-603.doi: 10.2337/dci19-0028

  12. Garber AJ, Abrahamson MJ, Barzilay JI, et al. ConsensusStatement by The American Association of Clinical Endocrinologistsand American College of Endocrinology on theComprehensive Type 2 Diabetes Management Algorithm- 2018 Executive Summary. Endocr Pract 2018; 24 (1): 91-120. doi:10.4158/CS-2017-0153.

  13. Ruiz de Adana MS, Domínguez-López M, Tapia MJ, dela Higuera M, et al. ¿Cómo cuantificar la variabilidadglucémica? Av Diabetol 2008; 24 (1): 77-81. URL: http://avancesendiabetologia.org/gestor/upload/revistaAvances/24-1.pdf#page=77

  14. Chehregosha H, Khamseh ME, Malek M, et al. A viewbeyond HbA1c: Role of continuous glucose monitoring.Diabetes Ther 2019; 10 (3): 853-63. doi: 10.1007/s13300-019-0619-1

  15. Danne T, Nimri R, Battelino, et al. International Consensuson Use of Continuous Glucose Monitoring. Diabetes Care2017; 40 (12): 1631-40. doi: 10.2337/dc17-1600

  16. Lavalle-González FJ, Antillón-Ferreira C, Flores-Caloca O, etal. Recomendaciones del uso de monitoreo continuo y evaluaciónde la variabilidad glucémica en diabetes. Med IntMex 2020; 36 (2): 185-98. doi: https://doi.org/10.24245/mim.v36i2.3055

  17. Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendationsfor standardizing glucose reporting and analysis tooptimize clinical decision making in diabetes: the AmbulatoryGlucose Profile (AGP). Diabetes Technol Ther 2013;15 (3): 198-211. doi: 10.1089/dia.2013.0051

  18. Feig DS, Donovan LE, Corcoy R, et al. CONCEPTT CollaborativeGroup. Continuous glucose monitoring inpregnant women with type 1 diabetes (CONCEPTT): amulticentre international randomised controlled trial.Lancet 2017; 390 (10110): 2347-59. doi: 10.1016/S0140-6736(17)32400-5

  19. Tumminia A, Milluzzo A, Festa C, et al. Efficacy of flash glucosemonitoring in pregnant women with poorly controlledpregestational diabetes (FlashMom): A randomized pilotstudy. Nutr Metab Cardiovasc Dis 2021; 31 (6): 1851-59.doi: 10.1016/j.numecd.2021.03.013

  20. Alharthi SK, Alyusuf EY, Alguwaihes AM, et al. The impact ofa prolonged lockdown and use of telemedicine on glycemiccontrol in people with type 1 diabetes during the COVID-19outbreak in Saudi Arabia. Diabetes Res Clin Pract 2021; 173:108682. doi: 10.1016/j.diabres.2021.108682

  21. Canecki Varzic S, Steiner K, et al. Assessment of FreeStyleLibre Flash Glucose Monitoring System Implementationin Real Life Clinical Setting: A Prospective ObservationalStudy. Diagnostics (Basel) 2021; 11 (2): 305. doi: 10.3390/diagnostics11020305

  22. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J,Weitgasser R. Novel glucose-sensing technology and hypoglycaemiain type 1 diabetes: a multicentre, non-masked,randomised controlled trial. Lancet 2016; 388 (10057):2254-63. doi:10.1016/S0140-6736(16)31535-5

  23. Zhang X, Jiang D, Wang X. The effects of the instantaneousscanning glucose monitoring system on hypoglycemia,weight gain, and health behaviors in patients with gestationaldiabetes: a randomised trial. Ann Palliat Med 2021;10 (5): 5714-20. doi: 10.21037/apm-21-439




2020     |     www.medigraphic.com